Sun Pharma's ILUMYA Is Approved For Psoriatic Arthritis, And Can Only Be Given In A Clinic

In this storySun Pharmaceutical Industries

The US Food and Drug Administration has approved Sun Pharmaceutical Industries' supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) to treat adults with active psoriatic arthritis, the company announced on 30 October from Mumbai and Princeton, New Jersey.

The approval adds a second indication to a drug the FDA first cleared in 2018 for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA is a monoclonal antibody targeting the p19 subunit of interleukin-23, a protein involved in inflammation.

It rests on two Phase 3 studies, INSPIRE-1 and INSPIRE-2, global multicentre randomised double-blind placebo-controlled trials of a 100 mg subcutaneous formulation given at weeks 0 and 4 and every 12 weeks thereafter. The drug showed superiority over placebo on the primary endpoint of ACR20 response at 24 weeks. Sun Pharma said safety findings were consistent with the drug's established profile with no new signals identified, and that the most common adverse reactions occurring in at least 3 per cent of patients receiving it for psoriatic arthritis were upper respiratory tract infections and COVID-19.

Rick Ascroft, North America chief executive of Sun Pharma, said the approval builds on the established clinical experience of ILUMYA in plaque psoriasis, and that as an IL-23 inhibitor administered exclusively by a healthcare provider it is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment or who may benefit from regular in-office care.

Psoriatic arthritis is a chronic inflammatory disease affecting peripheral and axial joints, entheses, digits and the skin. Sun Pharma cited data suggesting more than 15 per cent of people with psoriasis may have undiagnosed psoriatic arthritis. Existing treatment options include biologics targeting TNF and targeted synthetic agents.

Sun Pharma has taken the most obvious commercial weakness of this product and made it the headline.

Almost every modern biologic for inflammatory disease is designed so patients can inject themselves at home. Convenience is the feature manufacturers compete on. ILUMYA cannot be self-administered, and rather than treat that as a limitation to be managed, the company has built its positioning around it, describing the drug as being for adults who are unable to self-administer or who may benefit from regular in-office care.

There is a real patient group there. Hand and finger involvement is common in psoriatic arthritis, and dexterity problems make self-injection genuinely difficult for some people. Every-twelve-week dosing also means four clinic visits a year rather than fortnightly injections at home, which is a different proposition from the old infusion-centre model.

The less-stated reason is that provider-administered biologics sit in a different reimbursement channel in the United States from drugs dispensed through a pharmacy benefit, with different economics for the physicians administering them. A product that a clinic buys and bills for behaves differently in the market from one a patient collects. Sun Pharma has not framed it that way, but it is part of why this positioning is worth building a launch around.

The gap in the announcement is what the trials actually showed. Sun Pharma said INSPIRE-1 and INSPIRE-2 met their primary endpoint and that the drug beat placebo on ACR20 at 24 weeks, but published no response rates. In a class where competing products market specific ACR20 and ACR50 figures, choosing not to lead with yours is a decision, and the numbers will be available soon enough for anyone comparing options.

For Sun Pharma the value is less in the new patients than in the new prescribers.

ILUMYA has been a dermatology product since 2018, sold to doctors treating skin. Psoriatic arthritis is largely managed by rheumatologists. A second indication gives the same sales force a second specialty to call on, and gives the asset a reason to be considered by physicians who had no occasion to think about it before. The company's own figure, that more than 15 per cent of psoriasis patients may have undiagnosed psoriatic arthritis, is a statement about overlap in the existing prescriber base rather than about an untapped population.

That matters to a company in the middle of a long shift. Sun Pharma has spent a decade trying to move its earnings mix from generics, where price erosion is permanent, towards specialty products with patent protection. ILUMYA is one of the handful of assets that shift depends on, and indications are how you extend the useful life of a biologic without discovering a new molecule.

The constraint is the field it enters. Psoriatic arthritis already has TNF inhibitors, IL-17 inhibitors, JAK inhibitors and at least two other IL-23 agents, most of them from companies with far larger rheumatology sales organisations. ILUMYA arrives as a late entrant into a class where the first-line choices are established.

Which brings the strategy back to the one thing in the announcement that is genuinely differentiated, and it is not the molecule.

For daily, sharp analysis of the biggest moves in the Indian business and startup ecosystem, follow StartupFox.